4.6 Article

Functional Impact of Corticotropin-Releasing Factor Exposure on Tau Phosphorylation and Axon Transport

Journal

PLOS ONE
Volume 11, Issue 1, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0147250

Keywords

-

Funding

  1. NIH [AG032755, AG047484, AG010483, BX003040, AG005131, PN2 EY016525]
  2. Alzheimer's Art Quilt Initiative
  3. Alzheimer's Association
  4. Down syndrome Research and Treatment Foundation
  5. Larry L. Hillblom Foundation

Ask authors/readers for more resources

Stress exposure or increased levels of corticotropin-releasing factor (CRF) induce hippocampal tau phosphorylation (tau-P) in rodent models, a process that is dependent on the type-1 CRF receptor (CRFR1). Although these preclinical studies on stress-induced tau-P provide mechanistic insight for epidemiological work that identifies stress as a risk factor for Alzheimer's disease (AD), the actual impact of stress-induced tau-P on neuronal function remains unclear. To determine the functional consequences of stress-induced tau-P, we developed a novel mouse neuronal cell culture system to explore the impact of acute (0.5hr) and chronic (2hr) CRF treatment on tau-P and integral cell processes such as axon transport. Consistent with in vivo reports, we found that chronic CRF treatment increased tau-P levels and caused globular accumulations of phosphorylated tau in dendritic and axonal processes. Furthermore, while both acute and chronic CRF treatment led to significant reduction in CREB activation and axon transport of brain-derived neurotrophic factor (BDNF), this was not the case with mitochondrial transport. Acute CRF treatment caused increased mitochondrial velocity and distance traveled in neurons, while chronic CRF treatment modestly decreased mitochondrial velocity and greatly increased distance traveled. These results suggest that transport of cellular energetics may take priority over growth factors during stress. Tau-P was required for these changes, as co-treatment of CRF with a GSK kinase inhibitor prevented CRF-induced tau-P and all axon transport changes. Collectively, our results provide mechanistic insight into the consequences of stress peptide-induced tau-P and provide an explanation for how chronic stress via CRF may lead to neuronal vulnerability in AD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemistry & Molecular Biology

Interaction of MYC with host cell factor-1 is mediated by the evolutionarily conserved Myc box IV motif

L. R. Thomas, A. M. Foshage, A. M. Weissmiller, T. M. Popay, B. C. Grieb, S. J. Qualls, V. Ng, B. Carboneau, S. Lorey, C. M. Eischen, W. P. Tansey

ONCOGENE (2016)

Article Medicine, Research & Experimental

Amyloid precursor protein-mediated endocytic pathway disruption induces axonal dysfunction and neurodegeneration

Wei Xu, April M. Weissmiller, Joseph A. White, Fang Fang, Xinyi Wang, Yiwen Wu, Matthew L. Pearn, Xiaobei Zhao, Mariko Sawa, Shengdi Chen, Shermali Gunawardena, Jianqing Ding, William C. Mobley, Chengbiao Wu

JOURNAL OF CLINICAL INVESTIGATION (2016)

Article Cell Biology

Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity

Erin R. Aho, Jing Wang, Rocco D. Gogliotti, Gregory C. Howard, Jason Phan, Pankaj Acharya, Jonathan D. Macdonald, Ken Cheng, Shelly L. Lorey, Bin Lu, Sabine Wenzel, Audra M. Foshage, Joseph Alvarado, Feng Wang, J. Grace Shaw, Bin Zhao, April M. Weissmiller, Lance R. Thomas, Christopher R. Vakoc, Matthew D. Hall, Scott W. Hiebert, Qi Liu, Shaun R. Stauffer, Stephen W. Fesik, William P. Tansey

CELL REPORTS (2019)

Article Multidisciplinary Sciences

Inhibition of MYC by the SMARCB1 tumor suppressor

April M. Weissmiller, Jing Wang, Shelly L. Lorey, Gregory C. Howard, Ernest Martinez, Qi Liu, William P. Tansey

NATURE COMMUNICATIONS (2019)

Article Multidisciplinary Sciences

Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance

Lance R. Thomas, Clare M. Adams, Jing Wang, April M. Weissmiller, Joy Creighton, Shelly L. Lorey, Qi Liu, Stephen W. Fesik, Christine M. Eischen, William P. Tansey

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)

Article Biochemistry & Molecular Biology

WDR5 is a conserved regulator of protein synthesis gene expression

Audra F. Bryan, Jing Wang, Gregory C. Howard, Alissa D. Guarnaccia, Chase M. Woodley, Erin R. Aho, Eric J. Rellinger, Brittany K. Matlock, David K. Flaherty, Shelly L. Lorey, Dai H. Chung, Stephen W. Fesik, Qi Liu, April M. Weissmiller, William P. Tansey

NUCLEIC ACIDS RESEARCH (2020)

Article Cell Biology

Impact of WIN site inhibitor on the WDR5 interactome

Alissa D. Guarnaccia, Kristie L. Rose, Jing Wang, Bin Zhao, Tessa M. Popay, Christina E. Wang, Kiana Guerrazzi, Salisha Hill, Chase M. Woodley, Tyler J. Hansen, Shelly L. Lorey, J. Grace Shaw, William G. Payne, April M. Weissmiller, Edward T. Olejniczak, Stephen W. Fesik, Qi Liu, William P. Tansey

Summary: This study demonstrates how WIN site inhibitors alter the WDR5 interactome by using quantitative proteomics, showing that the inhibitors change the interaction of WDR5 with numerous proteins, including those related to the PI3K signaling pathway. The research also proves that the master kinase PDPK1 is a high-affinity binding protein for the WIN site, modulating gene transcription in the G2 phase of the cell cycle.

CELL REPORTS (2021)

Article Biology

MYC regulates ribosome biogenesis and mitochondrial gene expression programs through its interaction with host cell factor-1

Tessa M. Popay, Jing Wang, Clare M. Adams, Gregory Caleb Howard, Simona G. Codreanu, Stacy D. Sherrod, John A. McLean, Lance R. Thomas, Shelly L. Lorey, Yuichi J. Machida, April M. Weissmiller, Christine M. Eischen, Qi Liu, William P. Tansey

Summary: Research has shown that HCF-1, as a critical co-factor of MYC, significantly affects MYC activity. Modulation of the MYC-HCF-1 interaction can influence cell growth, metabolite profiles, global gene expression patterns, and tumor growth in vivo.

ELIFE (2021)

Article Biochemistry & Molecular Biology

Multiple interactions of the oncoprotein transcription factor MYC with the SWI/SNF chromatin remodeler

Chase M. Woodley, Alexander S. Romer, Jing Wang, Alissa D. Guarnaccia, David L. Elion, Jack N. Maxwell, Kiana Guerrazzi, Tyler S. McCann, Tessa M. Popay, Brittany K. Matlock, David K. Flaherty, Shelly L. Lorey, Qi Liu, William P. Tansey, April M. Weissmiller

Summary: The SWI/SNF chromatin remodeling complex's SNF5 subunit acts as a tumor suppressor by inhibiting MYC's ability to bind chromatin. This study found that MYC can interact with multiple SWI/SNF components independently of SNF5 and in SNF5-deficient cells, MYC interacts with remaining SWI/SNF components for a purpose different from chromatin remodeling. The interaction between MYC and SWI/SNF target genes in SNF5-null cells is associated with core biological functions of MYC related to protein synthesis.

ONCOGENE (2021)

Article Multidisciplinary Sciences

WIN site inhibition disrupts a subset of WDR5 function

Andrew J. Siladi, Jing Wang, Andrea C. Florian, Lance R. Thomas, Joy H. Creighton, Brittany K. Matlock, David K. Flaherty, Shelly L. Lorey, Gregory C. Howard, Stephen W. Fesik, April M. Weissmiller, Qi Liu, William P. Tansey

Summary: WDR5 plays a crucial role in the assembly of histone-modifying complexes and is a significant target for cancer treatment. Most drug discovery efforts focus on blocking the WIN site of WDR5. However, the application of WIN site inhibitors is complicated by the diverse functions of WDR5, and changes in H3K4me do not fully explain the transcriptional responses.

SCIENTIFIC REPORTS (2022)

Article Oncology

The SWI/SNF ATPase BRG1 facilitates multiple pro-tumorigenic gene expression programs in SMARCB1-deficient cancer cells

Kylie C. Moe, Jack N. Maxwell, Jing Wang, Cheyenne A. Jones, Grace T. Csaki, Andrea C. Florian, Alexander S. Romer, Daniel L. Bryant, Anthony L. Farone, Qi Liu, William P. Tansey, April M. Weissmiller

Summary: This study reveals the connection between residual SWI/SNF complexes and oncogenic processes, providing insights into the function of SWI/SNF in maintaining tumor cells.

ONCOGENESIS (2022)

Article Biochemistry & Molecular Biology

Synergistic action of WDR5 and HDM2 inhibitors in SMARCB1-deficient cancer cells

Andrea C. Florian, Chase M. Woodley, Jing Wang, Brian C. Grieb, Macey J. Slota, Kiana Guerrazzi, Chih-Yuan Hsu, Brittany K. Matlock, David K. Flaherty, Shelly L. Lorey, Stephen W. Fesik, Gregory C. Howard, Qi Liu, April M. Weissmiller, William P. Tansey

Summary: The study found that WIN site inhibitors can inhibit the proliferation of Rhabdoid tumors (RT) cells and predict that future strategies for treating RT could be based on dual inhibition of WDR5/HDM2.

NAR CANCER (2022)

Review Genetics & Heredity

Emerging Themes in Mechanisms of Tumorigenesis by SWI/SNF Subunit Mutation

Cheyenne A. Jones, William P. Tansey, April M. Weissmiller

Summary: This review summarizes the importance of the SWI/SNF chromatin remodeling complex and its mutations in cancer, particularly in transcriptional regulation. Studies have shown that SWI/SNF mutations lead to enhancer dysregulation, inhibiting development and differentiation while promoting stemness and self-renewal. Additionally, SWI/SNF perturbations intersect with oncoprotein transcription factors AP-1 and MYC to drive malignant transcriptional programs.

EPIGENETICS INSIGHTS (2022)

Article Biochemical Research Methods

Gene-specific quantification of nascent transcription following targeted degradation of endogenous proteins in cultured cells

Alissa D. Guarnaccia, April M. Weissmiller, William P. Tansey

Summary: The study introduces an approach that combines genome engineering to tag endogenous proteins for degradation with a streamlined nuclear run-on assay to obtain gene-specific information on transcriptional changes.

STAR PROTOCOLS (2021)

Article Genetics & Heredity

Targeting WDR5: A WINning Anti-Cancer Strategy?

Erin R. Aho, April M. Weissmiller, Stephen W. Fesik, William P. Tansey

EPIGENETICS INSIGHTS (2019)

No Data Available